These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33433132)

  • 1. Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma.
    Hung YP; Shao YY; Lee JM; Hsu C; Hsu CH; Yang MH; Chao Y
    J Chin Med Assoc; 2021 Feb; 84(2):144-150. PubMed ID: 33433132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
    Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
    Sangro B; Melero I; Wadhawan S; Finn RS; Abou-Alfa GK; Cheng AL; Yau T; Furuse J; Park JW; Boyd Z; Tang HT; Shen Y; Tschaika M; Neely J; El-Khoueiry A
    J Hepatol; 2020 Dec; 73(6):1460-1469. PubMed ID: 32710922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma.
    Roozitalab G; Abedi B; Imani S; Farghadani R; Jabbarzadeh Kaboli P
    Cancer Metastasis Rev; 2024 Sep; 43(3):889-918. PubMed ID: 38409546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.
    Dharmapuri S; Özbek U; Lin JY; Sung M; Schwartz M; Branch AD; Ang C
    Cancer Med; 2020 Jul; 9(14):4962-4970. PubMed ID: 32419290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
    Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
    Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
    Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
    Di Blasi D; Boldanova T; Mori L; Terracciano L; Heim MH; De Libero G
    Cell Mol Gastroenterol Hepatol; 2020; 9(2):195-218. PubMed ID: 31445190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
    J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
    Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
    Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression.
    Yang X; Shi J; Chen X; Jiang Y; Zhao H
    Oncologist; 2020 Jun; 25(6):470-474. PubMed ID: 32100934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
    Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
    Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.
    Tai D; Loke K; Gogna A; Kaya NA; Tan SH; Hennedige T; Ng D; Irani F; Lee J; Lim JQ; Too CW; Ng MCH; Tham CK; Lam J; Koo SL; Chong HS; Goh GB; Huang HL; Venkatanarasimha N; Lo R; Chow PKH; Goh BKP; Chung A; Toh HC; Thng CH; Lim TKH; Yeong J; Zhai W; Chan CY; Choo SP
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1025-1035. PubMed ID: 34695377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients.
    Tan Z; Chiu MS; Yang X; Yue M; Cheung TT; Zhou D; Wang Y; Chan AW; Yan CW; Kwan KY; Wong YC; Li X; Zhou J; To KF; Zhu J; Lo CM; Cheng AS; Chan SL; Liu L; Song YQ; Man K; Chen Z
    Gut; 2023 Aug; 72(8):1568-1580. PubMed ID: 36450387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1.
    Chen Z; Chen Y; Peng L; Wang X; Tang N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
    Saito R; Sawada Y; Nakamura M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
    Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
    BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.